Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Inmune Bio (INMB) over the last 6 years, with Q2 2025 value amounting to $511000.0.

  • Inmune Bio's Other Accumulated Expenses fell 191.94% to $511000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $511000.0, marking a year-over-year decrease of 191.94%. This contributed to the annual value of $517000.0 for FY2024, which is 572.6% up from last year.
  • Inmune Bio's Other Accumulated Expenses amounted to $511000.0 in Q2 2025, which was down 191.94% from $480000.0 recorded in Q1 2025.
  • Inmune Bio's 5-year Other Accumulated Expenses high stood at $778000.0 for Q3 2022, and its period low was $474000.0 during Q4 2021.
  • For the 5-year period, Inmune Bio's Other Accumulated Expenses averaged around $548722.2, with its median value being $531000.0 (2021).
  • As far as peak fluctuations go, Inmune Bio's Other Accumulated Expenses skyrocketed by 14947.37% in 2021, and later plummeted by 3624.68% in 2023.
  • Quarter analysis of 5 years shows Inmune Bio's Other Accumulated Expenses stood at $474000.0 in 2021, then rose by 29.96% to $616000.0 in 2022, then decreased by 20.62% to $489000.0 in 2023, then rose by 5.73% to $517000.0 in 2024, then dropped by 1.16% to $511000.0 in 2025.
  • Its last three reported values are $511000.0 in Q2 2025, $480000.0 for Q1 2025, and $517000.0 during Q4 2024.